Forest/Gedeon line up FDA meetings to pursue cariprazine
This article was originally published in Scrip
Executive Summary
Forest Laboratories and Gedeon Richter are "working with the US FDA to resolve the complete response letter for cariprazine in schizophrenia and bipolar mania," Forest has told Scrip. The update came with news that the companies have obtained positive top-line results from a Phase IIb trial evaluating the investigational antipsychotic in patients with bipolar depression.